Daniel Morchón-Araujo

3PUBLICATIONS
10CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|May 22, 2026
Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrent ARID1A-mutant lung adenocarcinoma: a case report.

|Jun 13, 2025
Emerging Immunotherapy Targets in Early Drug Development.

Daniel Morchón-Araujo, Greta Catani, Oriol Mirallas

|Sep 05, 2024
PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.

Eduardo Terán, Rebeca Lozano, César A Rodríguez

Pageof 1

Frequent Collaborators

1 joint publications

Eduardo Terán

1 joint publications

César A Rodríguez

1 joint publications

Juan Carlos Montero

1 joint publications

José María Sayagués